NO20060229L - Gaboxadol for the treatment of depression and other affective disorders - Google Patents

Gaboxadol for the treatment of depression and other affective disorders

Info

Publication number
NO20060229L
NO20060229L NO20060229A NO20060229A NO20060229L NO 20060229 L NO20060229 L NO 20060229L NO 20060229 A NO20060229 A NO 20060229A NO 20060229 A NO20060229 A NO 20060229A NO 20060229 L NO20060229 L NO 20060229L
Authority
NO
Norway
Prior art keywords
gaboxadol
depression
treatment
affective disorders
pharmaceutical composition
Prior art date
Application number
NO20060229A
Other languages
Norwegian (no)
Inventor
Bjarke Ebert
Connie Sanchez
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58707228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060229(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/DK2004/000459 external-priority patent/WO2004112786A2/en
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20060229L publication Critical patent/NO20060229L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Den foreliggende oppfinnelse vedrører anvendelse av gaboxadol for fremstilling av en farmasøytisk sammensetning for behandling av depresjon. Videre vedrører den anvendelsen av gaboxadol for fremstillingen av en farmasøytisk sammensetning for anvendelse i kombinasjon med en serotonin- reopptaksinhibitor eller enhver annen forbindelse, som forårsaker en forhøyelse i nivået av ekstiacellulært serotonin.The present invention relates to the use of gaboxadol in the manufacture of a pharmaceutical composition for the treatment of depression. Furthermore, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition for use in combination with a serotonin reuptake inhibitor or any other compound, which causes an increase in the level of extracellular serotonin.

NO20060229A 2003-06-25 2006-01-16 Gaboxadol for the treatment of depression and other affective disorders NO20060229L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300956 2003-06-25
DKPA200400016 2004-01-07
PCT/DK2004/000459 WO2004112786A2 (en) 2003-06-25 2004-06-25 Gaboxadol for treating depression and other affective disorders

Publications (1)

Publication Number Publication Date
NO20060229L true NO20060229L (en) 2006-01-16

Family

ID=58707228

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060229A NO20060229L (en) 2003-06-25 2006-01-16 Gaboxadol for the treatment of depression and other affective disorders

Country Status (10)

Country Link
KR (1) KR20060025192A (en)
AR (1) AR047550A1 (en)
CA (2) CA2692334A1 (en)
CL (2) CL2004001607A1 (en)
EA (1) EA200600101A1 (en)
IS (1) IS8138A (en)
ME (2) ME00030B (en)
NO (1) NO20060229L (en)
RS (1) RS20050911A (en)
TW (1) TW200509918A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3120856A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics, Inc. Gaboxadol for reducing risk of suicide and rapid relief of depression
JP2023526439A (en) 2020-05-20 2023-06-21 セルテゴ セラピューティクス インコーポレイテッド Cyclodeuterated gaboxadol and its use for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
TW200509918A (en) 2005-03-16
ME00030B (en) 2010-06-10
KR20060025192A (en) 2006-03-20
MEP1908A (en) 2010-02-10
RS20050911A (en) 2007-08-03
AR047550A1 (en) 2006-01-25
CL2010000166A1 (en) 2010-07-02
CL2004001607A1 (en) 2005-05-27
EA200600101A1 (en) 2006-06-30
CA2529805A1 (en) 2004-12-29
CA2692334A1 (en) 2004-12-29
IS8138A (en) 2005-11-21

Similar Documents

Publication Publication Date Title
NO20060242L (en) The combination of a serotonin reuptake inhibitor and agomelatine
EA201190217A1 (en) SUBSTITUTED 2-ACETAMIDO-5-ARIL-1,2,4-TRIAZOLONES AND THEIR APPLICATION
IL202106A0 (en) Gaboxadol for treating depression and other affective disorders
NO20082026L (en) Deazapurins useful as inhibitors of Janus kinases
EA200700035A1 (en) SULPHATE AND SULFAMIDE DERIVATIVES FOR THE TREATMENT OF EPILEPSY AND RELATED DI SORDERS
EA201370208A1 (en) RIFAXIMINE FORMS AND THEIR APPLICATION
EA200601553A1 (en) SUBSTITUTED BENZIMIDAZOLE-, BENZTRIASOLE- AND BENZIMIDAZOLONE-O-GLUCOSIDES
EA200901032A1 (en) COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS
EA200970337A1 (en) SODIUM-GLUCOSE 2 COPHANTER OF INHIBITORS AND METHODS OF THEIR APPLICATION
NO20083501L (en) Azaindoles useful as inhibitors of Janus kinases
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
EA200970581A1 (en) CRISTAL TREATMENT BASIS BACKGROUND
NO20064976L (en) Azanidols useful as inhibitors of rock and other protein kinases
NO20060402L (en) 3-amino choman and 2-aminotetraline derivatives
DK1937669T3 (en) New benzopyran derivatives such as potassium channel openers
BRPI0508254A (en) methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
EA201070327A1 (en) CATECHOLAMINE DERIVATIVES AND THEIR DEVICES
EA200702253A1 (en) PHARMACEUTICAL COMPOSITION
MA32776B1 (en) INHIBITORS OF AKT AND P70 S6 KINASE
EA201001747A1 (en) BENZOXASINIC DERIVATIVES, ACTING AS AN AGONIST BETA-2-ADRENOCEPTOR, FOR THE TREATMENT OF RESPIRATORY DISORDERS
CL2008003231A1 (en) Substituted 1,3-dihydro-5-isobenzofurancarbonitrile derivative compounds, selective serotonin reuptake inhibitors; pharmaceutical composition; preparation procedure; Useful in the treatment and / or prevention of premature ejaculation.
NO20083751L (en) Methods for the treatment of cognitive and other diseases
NO20076405L (en) Use of 24-nor-UDCA
ATE440836T1 (en) LINKS
ATE524463T1 (en) 4-CHROMENONYL-1,4-DIHYDROPYRIDINE CARBONITRILES AND THEIR USE

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104

FC2A Withdrawal, rejection or dismissal of laid open patent application